APOE epsilon-4 allele and cytokine production in Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 25, Issue 4, 2010, Pages 338-344

  Olgiati, Paolo ^a   Politis, Antonis ^b   Malitas, Petros ^c   Albani, Diego ^d   Dusi, Sabrina ^d   Polito, Letizia ^d   De Mauro, Stefania ^d   Zisaki, Aikaterini ^e   Piperi, Christina ^e   Stamouli, Evangelia ^b   Mailis, Antonis ^b   Batelli, Sara ^d   Forloni, Gianluigi ^d   De Ronchi, Diana ^a   Kalofoutis, Anastasios ^e,f   Liappas, Ioannis ^b   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c European Centre for the Quality of Life ECQuaL   (Greece)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

Alzheimer; APOE; Cytokine; In vivo; Inflammatory response

Indexed keywords

APOLIPOPROTEIN E4; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEPRESSION; DONOR; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE REPLICATION; GENETIC CORRELATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; OUTPATIENT; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; RATING SCALE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; MALE; PSYCHIATRIC STATUS RATING SCALES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949506459     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2344     Document Type: Article

References (51)

1. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. 1988. Cornell Scale for Depression in Dementia. Biol Psychiatr 23: 271-284.
2. Alvarez V, Mata IF, Gonzalez P, et al. 2002. Association between the TNFalpha-308 A/G polymorphism and the onset-age of Alzheimer disease. Am J Med Genet 114: 574-577.
3. American Psychiatric Association. 2002. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (revised) American Psychiatric Association: Washington DC.
4. Brown C, Choi E, Xu Q, Vitek M, Colton C. 2008. The APOE4 genotype alters the response of microglia and macrophages to 17beta-estradiol. Neurobiol Aging 29: 1783-1794.
5. Chao CC, Ala TA, Hu S, et al. 1994. Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol 1: 433-436.
6. Collins JS, Perry RT, Watson B Jr, et al. 2000. Association of a haplotype for tumor necrosis factor in siblings with late-onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. Am J Med Genet 96: 823-830.
7. Corder EH, Saunders AM, Strittmatter WJ, et al. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
8. Craig D, Hart DJ, McCool K, McIlroy SP, Passmore AP. 2004. The interleukin 1beta gene promoter polymorphism (-511) acts as a risk factor for psychosis in Alzheimer's dementia. Ann Neurol 56: 121-124.
9. Cummings J, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44: 2308-2314.
10. Du Y, Dodel RC, Eastwood BJ, et al. 2000. Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. Neurology 55: 480-483.
11. Egensperger R, Kösel S, von Eitzen U, Graeber M. 1998. Microglial activation in Alzheimer disease: association with APOE genotype. Brain Pathol 8: 439-447.
12. Erdfelder E, Faul F, Buchner A. 1996. GPOWER: a general power analysis program. Behav Res Meth Instrum Comput 28: 1-11.
13. Evin G, Sernee MF, Masters CL. 2006. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs 20: 351-372.
14. Ferrera P, Arias C. 2005. Differential effects of COX inhibitors against betaamyloid-induced neurotoxicity in human neuroblastoma cells. Neurochem Int 47: 589-596.
15. Folstein MF, Folstein SE, McHugh PR. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
16. Franceschi C, Valensin S, Lescai F, et al. 2001. Neuroinflammation and the genetics of Alzheimer's disease: the search for a pro-inflammatory phenotype. Aging (Milano) 13: 163-170.
17. Frey C, Bonert A, Kratzsch T, et al. 2006. Apolipoprotein E epsilon 4 is associated with an increased vulnerability to cell death in Alzheimer's disease. J Neural Transm 113: 1753-1761.
18. Ganguli R, Brar J, Rabin B. 1994. Immune abnormalities in schizophrenia: evidence for the autoimmune hypothesis. Harv Rev Psychiatr 2: 70-83.
19. Griffin W, Liu L, Li Y, Mrak R, Barger S. 2006. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation 3: 5.
20. Grimaldi LM, Casadei VM, Ferri C, et al. 2000. Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol 47: 361-365.
21. Irizarry MC, Deng A, Lleo A, et al. 2004. Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J Neurochem 90: 1132-1143.
22. Kim J, Stewart R, Kim S, et al. 2008. Methylenetetrahydrofolate reductase gene and risk of Alzheimer's disease in Koreans. Int J Geriatr Psychiatr 23: 454-459.
23. Kolsch H, Ptok U, Bagli M, et al. 2001. Gene polymorphisms of interleukin-1alpha influence the course of Alzheimer's disease. Ann Neurol 49: 818-819.
24. Lanzrein A, Johnston C, Perry V, et al. 1998. Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord 12: 215-227.
25. Li Y, Liu L, Barger S, Griffin W. 2003. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 23: 1605-1611.
26. Liao YF, Wang BJ, Cheng HT, Kuo LH, Wolfe MS. 2004. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem 279: 49523-49532.
27. Licastro F, Grimaldi LM, Bonafe M, et al. 2003. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 24: 921-926.
28. Licastro F, Porcellini E, Caruso C, Lio D, Corder E. 2007. Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation. Neurobiol Aging 28: 1637-1643.
29. Licastro F, Veglia F, Chiappelli M, Grimaldi LM, Masliah E. 2004. A polymorphism of the interleukin-1 beta gene at position +3953 influences progression and neuro-pathological hallmarks of Alzheimer's disease. Neurobiol Aging 25: 1017-1022.
30. Lombardi V, García MRC. 1998. Microglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypes. J Neurosci Res 54: 539-553.
31. Lynch J, Tang W, Wang H, et al. 2003. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 278: 48529-48533.
32. Maezawa I, Nivison M, Montine K, Maeda N, Montine T. 2006. Neurotoxicity from innate immune response is greatest with targeted replacement of E4 allele of apolipoprotein E gene and is mediated by microglial p38MAPK. FASEB J 20: 797-799.
33. McCulley MC, Day IN, Holmes C. 2004. Association between interleukin 1-beta promoter (-511) polymorphism and depressive symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 124: 50-53.
34. Mrak RE, Griffin WS. 2001. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging 22: 903-908.
35. Murphy GM Jr, Claassen JD, DeVoss JJ, et al. 2001. Rate of cognitive decline in AD is accelerated by the interleukin-1 alpha -889 *1 allele. Neurology 56: 1595-1597.
36. Myers RH, Schaefer EJ, Wilson PW, et al. 1996. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology 46: 673-677.
37. Poirier J. 1994. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 12: 525-530.
38. Politis AM, Mayer LS, Passa M, Maillis A, Lyketsos CG. 2004. Validity and reliability of the newly translated Hellenic Neuropsychiatric Inventory (H-NPI) applied to Greek outpatients with Alzheimer's disease: a study of disturbing behaviors among referrals to a memory clinic. Int J Geriatr Psychiatr 19: 203-208.
39. Rebeck GW. 2000. Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease. Neurosci Lett 293: 75-77.
40. Roses AD. 1996. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Ann Rev Med 47: 387-400.
41. Saunders AM, Strittmatter WJ, Schmechel D, et al. 1993. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472.
42. Serretti A, Olgiati P, Politis A, et al. 2008. Lack of association between Interleukin-1 alpha rs1800587 polymorphism and Alzheimer's disease in two independent European samples. J Alzheimer's Dis 16: 181-187.
43. Sheng JG, Ito K, Skinner RD, et al. 1996. In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 7: 761-767.
44. Sheng JG, Zhu SG, Jones RA, Griffin WS, Mrak RE. 2000. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp Neurol 163: 388-391.
45. Shibata N, Ohnuma T, Takahashi T, et al. 2002. Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. Am J Med Genet 114: 436-439.
46. Sleegers K, van Duijn C. 2001. Alzheimer's diesease: genes, pathogenesis and risk prediction. Commun Genet 4: 197-203.
47. StrittmatterWJ, Saunders AM, Schmechel D, et al. 1993. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90: 1977-1981.
48. Tachida Y, Nakagawa K, Saito T, et al. 2008. Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. J Neurochem 104: 1387-1393.
49. Tarkowski E. 2002. Cytokines in dementias. Curr Drug Targets Inflamm Allergy 1: 193-200.
50. Vitek M, Brown C, Colton C. 2007. APOE genotype-specific differences in the innate immune response. Neurobiol Aging 20.
51. Vlad S, Miller D, Kowall N, Felson D. 2008. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70: 1672-1677.